Do You Need Progesterone With Vaginal Estrogen?

No — most women using an FDA-approved low-dose local vaginal estrogen do not need progesterone solely to protect the uterine lining, even with a uterus. The answer changes with Femring or another systemic estrogen, a high-dose cream regimen, an unclear compounded formula, or another estrogen patch, pill, gel, spray, pellet, or injection. Postmenopausal bleeding needs prompt evaluation.

Here's the part almost nobody tells you: the word “vaginal” describes where the medicine goes, not how strong it is. Across the estradiol-containing labeled regimens we checked, the amount placed or released each week runs from 8 micrograms to about 2,800 micrograms — a 350-fold spread. Estring and Femring are both rings. One is local. One is systemic.

So “do you need progesterone with vaginal estrogen?” is not really one question. It is one question with four forks:

Uterus + exact product + exact dose + any other estrogen.

---

Is this page for you?

Yes, if: you have a uterus, you were prescribed vaginal estrogen for dryness, burning, painful sex, or urinary symptoms, and a package insert, pharmacist, clinician, or friend has told you that you also need progesterone.

A general answer is not enough if: you use Femring; you also use a patch, pill, gel, spray, pellet, or injection; your cream dose is high or unclear; your product is compounded; you have had an endometrial ablation or an unclear “partial hysterectomy”; or you have had any bleeding since menopause.

Stop here and contact your clinician promptly if: you have had bleeding or spotting after menopause. Most causes are not cancer, but postmenopausal bleeding always needs evaluation before you change estrogen or progesterone.

---

The 30-second answer table

The standard answer is no for low-dose local inserts, Estring, and ordinary maintenance cream regimens. It becomes yes or needs individual review when the product is systemic, the cream regimen is high-dose or prolonged, another systemic estrogen is present, or postmenopausal bleeding has occurred.

Your situation	Bottom line
Low-dose insert such as Imvexxy 4 or 10 mcg, Vagifem/Yuvafem, or a 10 mcg generic + uterus	No routine progestogen needed solely for this product
Estring + uterus	No routine progestogen needed solely for Estring
Estradiol cream at a standard maintenance regimen + uterus	Usually no — but know the grams and frequency
Premarin Vaginal Cream 0.5 g twice weekly + uterus	No routine progestogen under low-dose guidance
Femring + uterus	Yes — treat it as systemic estrogen
High-dose vaginal cream used beyond a short loading phase	This is not the simple low-dose rule; ask specifically about endometrial protection
Patch, pill, gel, spray, pellet, or injection + uterus	You need an endometrial-protection plan because of the systemic estrogen
Total hysterectomy	No progesterone for uterine protection because there is no uterine lining
Any bleeding after menopause	Get evaluated before adding, stopping, or changing anything

---

The trap that sends women here in the first place

Two women can both say, “I use a vaginal estrogen ring.” One is using Estring, which releases about 7.5 micrograms of estradiol a day and treats local vaginal symptoms. The other is using Femring, which releases 0.05 or 0.10 milligrams a day, treats hot flashes as well as vaginal symptoms, and delivers systemic estrogen.

Same shape. Same placement. Same 90-day schedule. Opposite answers to your question.

Cream does the same thing in a quieter way. “Estradiol cream 0.01%” tells you the concentration. It does not tell you the dose. One gram twice a week and four grams every day come from the same tube and deliver radically different weekly amounts.

That is why this page is built around your exact product and dose, not around the word “vaginal.”

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

---

What we actually verified for this page

On August 7, 2026, we reviewed the current US prescribing information for six vaginal estrogen products or formulations — Imvexxy, 10 mcg estradiol vaginal inserts, Estring, Femring, estradiol vaginal cream 0.01%, and Premarin Vaginal Cream — plus two other prescription treatments for genitourinary syndrome of menopause: Intrarosa and Osphena.

For each, we recorded the labeled regimen, progestogen language, current boxed-warning status, and product-specific pharmacokinetic or endometrial data where the label provides it. We converted labeled doses to weekly amounts ourselves and mark that arithmetic as our calculation.

We compared the labels against guidance from The Menopause Society, the Endocrine Society, the Society of Obstetricians and Gynaecologists of Canada, and the 2025 AUA/SUFU/AUGS guideline.

The damaging admission: randomized trials have not established endometrial safety beyond one year for low-dose vaginal estrogen. Long-term reassurance comes mainly from observational evidence, not decades-long randomized trials. That gap is real. It does not turn the guideline answer into “yes,” but it is why bleeding still gets evaluated and why “reassuring” is more honest than “proven forever.”

What we did not do: review this page with a clinician, use any product ourselves, or assess anyone's individual eligibility. See our medical review policy.

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

---

Do you need progesterone with vaginal estrogen?

For recommended low-dose local vaginal estrogen, major menopause guidance does not call for a routine progestogen. The Menopause Society, Endocrine Society, and SOGC say that explicitly. The 2025 AUA/SUFU/AUGS guideline also treats local low-dose therapy as a distinct category and advises against routine endometrial surveillance solely because a woman uses it.

Four things settle your answer. Keep them in this order:

1. Do you have a uterus or any uterine lining left? If not, there is no lining to protect. Ablation and an unclear “partial hysterectomy” need their own answer.
2. What exactly is the product? Brand and strength, not “the ring” or “the cream.”
3. What dose and how often? For creams, this means grams per application and applications per week — not the percentage on the tube.
4. Are you using any other estrogen? A patch, pill, gel, spray, pellet, injection, or Femring changes the answer.

Now the part that matters most: what “a progestogen is not indicated” means — and what it does not.

It means current guidance does not require you to add a second hormone solely because you use a standard low-dose local vaginal estrogen.

It does not mean you should stop progesterone you already take. If you use a systemic patch and progesterone, the progesterone may be protecting your uterine lining from the patch. Stopping it because your vaginal insert does not independently require it would be a serious mistake. We say this early because it is the one way this page could hurt someone.

It does not mean zero estrogen reaches the bloodstream. A small amount can. The amount varies by product, dose, formulation, placement, and the condition of the vaginal tissue.

For the broader treatment overview—forms, symptoms, and where local therapy fits—see our vaginal estrogen guide.

It does not mean bleeding can be ignored. Postmenopausal bleeding gets evaluated no matter which product you use.

A vocabulary note: progesterone is the naturally occurring hormone; progestin is a synthetic compound with progesterone-like effects; progestogen is the umbrella term for both. Guidelines and labels often use “progestogen.” This page uses “progesterone” when speaking plainly unless the distinction matters.

---

Why does your package insert say to consider progesterone?

Because US labels for several low-dose vaginal estrogens still carry class language shaped by systemic-estrogen evidence and the absence of definitive long-term product-specific trials. That label language is real and should not be hidden. It is also not evidence that a 4 or 10 microgram vaginal insert caused the same risks seen with systemic oral estrogen.

Open the current Imvexxy prescribing information. The product comes in a 4 microgram dose, yet its dosage section says clinicians should consider adding a progestogen when prescribing estrogen to a woman with a uterus. It also has a dedicated section on adding a progestogen after hysterectomy status is considered.

On a four-microgram insert.

That same label reports a pharmacokinetic study in which the mean estradiol level after 14 days was 3.6 pg/mL with Imvexxy 4 mcg and 4.3 pg/mL with placebo. That does not mean Imvexxy lowers estrogen. It means the systemic signal at that dose was small enough to sit inside normal between-group measurement variation.

A 2021 Imvexxy endometrial study reported no meaningful endometrial change after 12 weeks, but it did not provide decades of follow-up. That is the collision you are seeing in the paperwork: low systemic exposure and reassuring short-term data on one side; class warning language and missing long-term randomized evidence on the other.

So we are not going to tell you the insert is “wrong.” We are going to tell you exactly what it is: a regulatory label that applies broad estrogen precautions while professional guidance separately distinguishes recommended low-dose local therapy from systemic estrogen.

Not sure whether your situation is the straightforward low-dose one? Use Find My HRT Path to sort the route, product, and safety flags before your next consult. It takes about 90 seconds and does not require an email address.

---

Which vaginal estrogen are you actually using?

“Vaginal estrogen” is a route, not a dose. Across the estradiol products and labeled regimens below, the amount placed or released each week ranges from 8 to 2,800 micrograms. That table does not tell you how much reaches your bloodstream; it tells you why the product name, grams, and schedule matter more than the word “vaginal.”

This is an original HRT Index comparison. We took the strength and schedule from each current label and converted them to a weekly amount. No single product label publishes the products side by side.

The vaginal estrogen dose ladder

Product or regimen	Hormone	Labeled maintenance or use pattern	Amount placed or released per week	Our classification for this decision
Imvexxy 4 mcg	Estradiol	1 insert twice weekly after the 2-week loading phase	8 mcg	Low-dose local
Imvexxy 10 mcg	Estradiol	1 insert twice weekly after the 2-week loading phase	20 mcg	Low-dose local
Vagifem/Yuvafem or 10 mcg generic insert	Estradiol	1 insert twice weekly after the 2-week loading phase	20 mcg	Low-dose local
Estring	Estradiol	7.5 mcg released daily; ring replaced every 90 days	52.5 mcg released	Low-dose local
Estradiol cream 0.01% — maintenance	Estradiol	1 g, 1–3 times weekly	100–300 mcg	Local maintenance regimen; dose still matters
Premarin Vaginal Cream — dyspareunia regimen	Conjugated estrogens	0.5 g twice weekly	0.625 mg conjugated estrogens	Low-dose local regimen; not convertible to estradiol mcg
Femring 0.05 mg/day	Estradiol acetate	Ring replaced every 90 days	350 mcg estradiol released	Systemic
Femring 0.10 mg/day	Estradiol acetate	Ring replaced every 90 days	700 mcg estradiol released	Systemic
Estradiol cream 0.01% — labeled starting range	Estradiol	2–4 g daily for 1–2 weeks before step-down	1,400–2,800 mcg	Higher-dose loading window; do not treat as indefinite maintenance
Premarin Vaginal Cream — top labeled cyclic dose	Conjugated estrogens	Up to 2 g daily for 21 days, then 7 days off	1.25 mg conjugated estrogens per treatment day	Systemic-dose territory in Endocrine Society guidance

Weekly figures are The HRT Index's arithmetic from labeled strengths and schedules. “Placed or released” is not the same as “absorbed.” Conjugated estrogens are not converted to estradiol equivalents.

Imvexxy 4 mcg twice weekly places 8 mcg of estradiol in the vagina per week. Estradiol cream at its labeled 4 g daily starting dose places 2,800 mcg per week. Both are prescribed vaginally. They are not the same dose.

Three caveats keep this table honest:

One — amount placed is not amount absorbed. Formulation matters. A ring that slowly releases hormone does not behave like the same numerical amount in cream, and conjugated estrogens cannot be treated as estradiol milligram for milligram.

Two — the cream rows include short loading regimens. A brief loading phase is not the same as staying at a high dose for months. The question becomes more urgent when the high end continues beyond the labeled step-down without a clear reason.

Three — this table classifies labeled regimens, not you. Your medical history, other hormones, bleeding history, and exact instructions can still change the plan.

Have the tube, box, or pharmacy label in front of you? Write down the brand, concentration, grams per dose, and days per week. Then use Find My HRT Path to build the right question list for your consult.

---

What does each product label say about progesterone?

The current labels do not speak with one voice. Several low-dose vaginal estrogen labels still tell women with a uterus to discuss or consider a progestogen. Estring lost its boxed warning in February 2026 but still carries systemic-risk discussion. Femring is systemic and retains the ordinary systemic-estrogen rule. Intrarosa and Osphena are different drugs, not vaginal estrogens.

The eight-label progesterone ledger

Product	What the current US label says	Boxed-warning status checked August 7, 2026	Practical interpretation
Estring	Systemic absorption occurs but exposure is generally lower than with systemic estrogen; the relevance of systemic estrogen risks is not known. It discusses risks of combining estrogen with a progestogen.	No boxed warning after the February 2026 FDA update	Low-dose local ring; routine progestogen is not recommended solely for Estring
Imvexxy 4/10 mcg	Says to consider adding a progestogen for a woman with a uterus and retains a dedicated progestogen section	Older full estrogen boxed warning remains	Guidance still treats recommended low-dose local use as not requiring routine progestogen
10 mcg estradiol insert / Vagifem-type generic	Patient information tells women with a uterus to discuss whether adding a progestogen is right	Older full estrogen boxed warning remains	Low-dose local maintenance regimen; no routine progestogen under major guidance
Estradiol vaginal cream 0.01%	Patient information says addition of a progestin is generally recommended for a woman with a uterus	Older full estrogen boxed warning remains	Maintenance dose may fit low-dose guidance; high or prolonged daily doses need separate review
Premarin Vaginal Cream	Says a progestin should be considered for a woman with a uterus	Older full estrogen boxed warning remains	0.5 g regimens differ from 2 g daily; do not answer from the product name alone
Femring	Patient information says adding a progestin is generally recommended for a woman with a uterus	Full systemic estrogen warning remains	Systemic estrogen: endometrial protection is generally needed if the uterus is present
Intrarosa (prasterone)	Does not instruct users to add progesterone; US label focuses on undiagnosed bleeding and breast-cancer history because prasterone is metabolized to estrogen	No boxed warning	Not an estrogen product; do not add progesterone on your own
Osphena (ospemifene)	Label warns of endometrial agonist effects and says progestin use with Osphena was not evaluated in trials	Boxed warning for endometrial cancer and cardiovascular disorders	Oral SERM with its own monitoring and bleeding rules; not part of the simple vaginal-estrogen exemption

This table exposes the real problem: a label can be internally conservative while a specialty guideline makes a route-and-dose distinction the label does not turn into a clean yes/no instruction. That is why a pharmacist reading the insert and a menopause specialist reading the guidelines can sound like they disagree.

The answer is not to pretend the label does not exist. The answer is to classify the product correctly.

---

Estring vs Femring: why do two vaginal rings have opposite answers?

Estring releases 7.5 micrograms of estradiol per day and treats local vaginal symptoms. Femring releases 0.05 or 0.10 milligrams per day and treats hot flashes as well as vaginal symptoms, which makes it systemic estrogen. If you have a uterus and use Femring, its label says adding a progestin is generally recommended.

Question	Estring	Femring
Where does it go?	Vagina	Vagina
How long does it stay?	90 days	90 days
Daily delivery	7.5 mcg estradiol	0.05 or 0.10 mg estradiol
Approximate weekly release	52.5 mcg	350–700 mcg
Approved to treat	Local vulvar and vaginal atrophy symptoms	Hot flashes and vulvar/vaginal atrophy symptoms
Drug category for this question	Low-dose local	Systemic
Current boxed warning	None	Full systemic warning
Progestogen with a uterus	Not routinely indicated solely for Estring	Generally recommended

The easiest tell is the indication. A drug approved to treat hot flashes is acting beyond the vaginal tissue. Femring is systemic hormone therapy delivered through a vaginal ring. Estring is a local therapy.

The brands are one letter apart. The weekly release is about 7 to 13 times different, and the treatment intent is different. Check the box before you do anything else.

---

Do you need progesterone with vaginal estrogen cream?

Usually not with a standard low-dose maintenance regimen, but “cream” is not a dose. Estradiol cream 0.01% can be prescribed from 1 g one to three times weekly up to a short 2–4 g daily loading phase. Premarin can range from 0.5 g twice weekly to 2 g daily in a cyclic regimen. Those are not interchangeable exposure levels.

Here is the calculation women are rarely shown:

Concentration × grams per application × applications per week = weekly amount placed.

For estradiol cream 0.01%:

• 0.01% means 0.1 mg estradiol per gram of cream.
• 1 g twice weekly = 0.2 mg, or 200 mcg, per week.
• 4 g daily = 2.8 mg, or 2,800 mcg, per week.

Same tube. Fourteen-fold difference.

The Endocrine Society draws a line that needs to be explicit: high-dose vaginal creams can produce systemic estrogen levels, and concomitant progestogen is needed with those preparations when a uterus is present. Its dose table classifies vaginal estradiol above 0.5 mg or vaginal conjugated estrogens above 0.5 mg as systemic-dose territory. A 2 g Premarin dose contains 1.25 mg conjugated estrogens and clearly crosses that threshold.

The standard estradiol 0.01% cream loading range of 2–4 g contains 0.2–0.4 mg estradiol per day. The same guideline says randomized trial data are not available for that FDA-labeled 2–4 g starting regimen. That does not mean every short loading phase automatically requires a new long-term medication. It means you should not use the blanket “vaginal estrogen never needs progesterone” answer for a high-dose, prolonged, or nonstandard cream regimen.

The Premarin dose that deserves a direct question

A 2019 systematic review covered 20 randomized trials and 2,983 women using vaginal estrogens. Endometrial cancer occurred in 0.03% and hyperplasia in 0.4%. The authors described the findings as sporadic except at 1.25 mg conjugated equine estrogens.

That 1.25 mg amount is exactly what 2 g of Premarin Vaginal Cream contains.

Premarin's own 52-week endometrial study is reassuring — but it studied 0.5 g regimens, not 2 g daily. It found no endometrial hyperplasia or carcinoma with 0.5 g twice weekly or 0.5 g daily for 21 days followed by 7 days off.

So the high-end labeled dose and the long-term studied dose are not the same. That is not proof that a short 2 g loading phase is unsafe. It is a reason to ask a much sharper question if you have remained at the high end for months:

“Is this still a loading dose, or is this now my maintenance dose — and what is the endometrial-protection plan at this amount?”

One more transparency point: several authors of the 2019 review had financial relationships with TherapeuticsMD, the manufacturer associated with Imvexxy. That is why this page does not rely on that review alone; it cross-checks labels, independent guidelines, and observational data.

---

How much estrogen from low-dose vaginal products reaches your blood?

Very little from the lowest-dose products, but not literally zero. Imvexxy's label reports a mean estradiol level of 3.6 pg/mL with the 4 mcg dose after 14 days, compared with 4.3 pg/mL on placebo. Estring reports steady-state levels around 7–8 pg/mL through one year and about 8% of its released dose absorbed unchanged.

The Imvexxy label gives unusually useful numbers:

Group after 14 daily doses	Mean estradiol Cavg	Mean estradiol Cmax
Imvexxy 4 mcg	3.6 pg/mL	4.8 pg/mL
Imvexxy 10 mcg	4.6 pg/mL	7.3 pg/mL
Placebo	4.3 pg/mL	5.5 pg/mL

The 4 mcg group's mean was lower than placebo. Again, that does not mean the medicine lowers estrogen. It means the systemic contribution was small enough to disappear inside normal variation between groups.

Estring tells the same story from another angle. Its current label reports mean steady-state estradiol estimates of 7.8, 7.0, 7.0, and 8.1 pg/mL at weeks 12, 24, 36, and 48. It estimates that about 8% of the daily amount released locally is absorbed unchanged.

Those numbers explain why recommended low-dose local products are treated differently from a systemic patch, pill, or Femring. They do not erase individual variation, and they do not turn a blood test into a home safety test.

---

Can vaginal estrogen thicken the uterine lining or cause endometrial cancer?

Available evidence is reassuring for recommended low-dose local therapy, not absolute. A systematic review of 20 randomized trials found endometrial cancer in 0.03% and hyperplasia in 0.4%. In the Women's Health Initiative Observational Study, vaginal estrogen users did not have a statistically significant increase in endometrial cancer compared with nonusers over a median 7.2 years.

The WHI observational analysis followed 45,663 postmenopausal women aged 50 to 79 who were not using systemic estrogen during follow-up. Among women with a uterus, vaginal estrogen use was not associated with a statistically significant difference in endometrial cancer, breast cancer, stroke, colorectal cancer, or venous thromboembolism.

That is meaningful reassurance. It is not a randomized trial. Vaginal estrogen use was self-reported, and women who receive and continue treatment can differ from nonusers in ways an observational study cannot fully remove.

Now the counterweight that belongs right next to the reassuring numbers.

The 2025 AUA/SUFU/AUGS guideline reviewed short-term studies of endometrial outcomes. In 6 of 10 studies running up to 36 weeks, some endometrial-related findings were reported, including vaginal bleeding, small changes in endometrial thickness, proliferative endometrium, and one case of hyperplasia within a polyp.

That is not “nothing.” It is also not a recommendation to add progesterone routinely. The same guideline says clinicians should not perform endometrial surveillance solely because a woman uses local low-dose vaginal estrogen. The practical rule is simpler:

• No routine ultrasound or biopsy merely because you use a standard low-dose product.
• Prompt evaluation if bleeding occurs.
• A separate plan for high-dose, prolonged, nonstandard, compounded, or systemic regimens.

And the limitation inside The Menopause Society's own statement remains: randomized endometrial-safety data beyond one year are lacking.

Reassuring is the honest word. Proven forever is not.

Does this sound like your situation — a low-dose product, no bleeding, and a prescriber who never explained the difference? Use Find My HRT Path to see what belongs in a routine online visit and what belongs in person.

---

What do the major guidelines say about progesterone and vaginal estrogen?

Three major guidance bodies explicitly say a routine progestogen is not needed with low-dose vaginal estrogen. The 2025 AUA/SUFU/AUGS guideline does not frame the issue in the same sentence, but it strongly recommends local low-dose vaginal estrogen for appropriate GSM symptoms and advises against routine endometrial surveillance solely because of its use.

Guideline body	Year	What it says	Strength or limitation
The Menopause Society	2020 GSM statement	A progestogen is not indicated with low-dose vaginal estrogen, vaginal DHEA, or ospemifene	Notes endometrial safety has not been studied in trials beyond 1 year
The Menopause Society	2022 hormone therapy statement	Progestogen is not advised with low-dose vaginal estrogen for GSM	Allows individualized consideration in women at increased endometrial risk
Endocrine Society	2015	Suggests against adding a progestogen with low-dose vaginal estrogen	Weak recommendation, very-low-quality evidence; promptly evaluate bleeding
SOGC	2021	Clinically significant systemic absorption does not occur with low-dose therapy, so concomitant progestogen is not needed	Strong recommendation, high-quality evidence in its grading system
AUA/SUFU/AUGS	2025	Recommends local low-dose vaginal estrogen for appropriate GSM indications and says not to perform routine endometrial surveillance solely because of its use	Strong treatment recommendation; surveillance statement based on available evidence and expert consensus

The wording and grading differ. The low-dose conclusion does not.

But “low-dose” is doing real work in every one of those sentences. The Endocrine Society separately says high-dose vaginal creams can produce systemic levels and need concomitant progestogen when the uterus is present. That distinction belongs in the headline answer, not buried in a footnote.

---

What if you also use an estrogen patch, pill, gel, spray, pellet, or injection?

Then the systemic product determines your endometrial-protection requirement. Adding low-dose vaginal estrogen does not cancel, replace, or usually increase that requirement. If you have a uterus and were prescribed progesterone with systemic estrogen, do not stop it because you learned that the vaginal product does not independently require it.

The faulty logic looks like this:

“My vaginal estrogen does not need progesterone. So I do not need progesterone.”

The first sentence can be true. The second does not follow if another estrogen in your regimen is systemic.

Two products, two jobs:

• Systemic estrogen treats whole-body symptoms such as hot flashes and night sweats.
• Low-dose local vaginal estrogen treats genitourinary symptoms such as dryness, burning, painful sex, urinary urgency, and recurrent urinary tract infections.

Using both is common when systemic therapy does not fully resolve vaginal or urinary symptoms. It does not automatically mean the systemic dose is wrong.

Before changing anything, write down every hormone you use — including products prescribed by different clinicians, products used only occasionally, pellets, injections, and rings. Then ask which product the progesterone was prescribed to protect you from.

For the full add-on question, see can you use vaginal estrogen with systemic HRT?.

---

What if you had a hysterectomy, a partial hysterectomy, or an endometrial ablation?

After a confirmed total hysterectomy, there is no uterine lining to protect, so progesterone is not needed for endometrial protection. A supracervical hysterectomy and endometrial ablation are different. “Partial hysterectomy” is also an imprecise phrase, so the operative report matters more than the nickname you were given.

Total hysterectomy: the uterus is removed. Endometrial protection is no longer the reason to prescribe progesterone. Some estrogen labels note that a progestogen may still be considered in women with known residual endometriosis after hysterectomy. That is a separate individualized question.

Supracervical hysterectomy: the uterine body is removed while the cervix remains. Most endometrium is removed, but small amounts of endometrial tissue can remain in the cervical stump. If you still have cyclic spotting or are unsure what surgery was performed, ask for the operative report before making assumptions.

Endometrial ablation: the uterus remains. Ablation destroys endometrial tissue but does not guarantee every cell is gone forever. For a standard low-dose local vaginal product, the general low-dose rule may remain unchanged. If systemic estrogen is anywhere in the regimen, ablation does not automatically put you in the “no uterus” group.

The cleanest question is not “Did I have surgery?” It is:

“Do I still have a uterus or any endometrial tissue that changes the protection plan for this exact estrogen regimen?”

---

Is adding progesterone “just to be safe” harmless?

No. It is a trade, not a free insurance policy. Progesterone and progestins can cause their own adverse effects, and systemic estrogen-plus-progestogen risk data are not identical to estrogen-alone data. That does not make progesterone bad; it makes “might as well” a poor reason to add a prescription hormone.

A lot of women land here hoping the answer is no because progesterone has made them feel awful: drowsiness, dizziness, bloating, breast tenderness, mood changes, or morning grogginess. Wanting to know whether you actually need it is legitimate.

So let us be straight in both directions.

Adding a progestogen you do not need is not neutral. It is another prescription with side effects, contraindications, and a reason that should be explainable.

Progesterone is genuinely protective when it is needed. If you have a uterus and use systemic estrogen, endometrial protection is not a nuisance add-on. It is preventing a real risk.

Label risk language needs context. Several low-dose estrogen labels discuss possible risks of combining estrogen and a progestogen, including breast-cancer findings from systemic hormone-therapy studies. That does not prove the same risk magnitude when a progestogen is paired with a tiny local dose. It does prove that adding a second hormone should be a deliberate decision, not a reflex.

If your prescriber recommends progesterone because of past hyperplasia, a high-dose cream regimen, a systemic product, residual endometrium, or another fact in your chart, ask them to name the reason. A clear reason is the point.

---

What about Intrarosa and Osphena?

Intrarosa and Osphena treat menopause-related vaginal symptoms, but neither is a vaginal estrogen. Intrarosa is a vaginal prasterone insert. Osphena is an oral selective estrogen receptor modulator with endometrial agonist effects and a boxed warning. Do not use the simple low-dose-vaginal-estrogen rule as a substitute for either product's own label.

Intrarosa

Intrarosa contains 6.5 mg prasterone, also called DHEA, and is inserted vaginally once daily. Prasterone is converted inside the body to estrogens and androgens. The current US label has no boxed warning. It does contraindicate use with undiagnosed abnormal genital bleeding and warns women with current or past breast cancer that estrogen is a metabolite of prasterone.

The Menopause Society's 2020 statement says a progestogen is not indicated with vaginal DHEA. European product information is even more explicit that a progestagen is not recommended when systemic estrogen exposure remains within the normal postmenopausal range.

That does not turn Intrarosa into estrogen. It means the endometrial-protection answer is still generally no — but for a different drug with a different evidence package.

Osphena

Osphena is a 60 mg oral tablet. It is a SERM: it blocks estrogen-like effects in some tissues and has estrogen-agonist effects in others. In the endometrium, its current label says it acts as an agonist.

The current label reports, through up to 52 weeks:

• Endometrial thickness of at least 5 mm: 101.4 per 1,000 women on Osphena vs 20.9 per 1,000 on placebo
• Proliferative endometrium: 26.3 per 1,000 vs 0 on placebo
• Uterine polyps: 19.6 per 1,000 vs 8.3 per 1,000 on placebo
• One case of simple hyperplasia without atypia
• No endometrial cancer cases in the trials through 52 weeks

These are the current figures in the label revised February 2025.

The label also states that using progestins with Osphena was not evaluated in clinical trials. So this is not a place to improvise progesterone. The rule is: use Osphena exactly as prescribed and report postmenopausal bleeding promptly.

---

What about compounded vaginal estrogen or estriol?

A compounded finished product cannot automatically inherit the no-progesterone answer from an FDA-approved low-dose product. Compounded drugs are not FDA-approved, and the exact finished formula does not automatically come with FDA-reviewed formulation-specific pharmacokinetic, dose-response, manufacturing, or endometrial-safety evidence.

Some hormones used in compounding have published literature. That does not validate every concentration, base, applicator amount, or absorption profile of an individually compounded preparation.

That is a structural regulatory difference, not an attack on your pharmacist.

Compounded and FDA-approved are separate categories, and this page keeps them separate. Compounded does not mean more natural, safer, or equivalent. Compounding can serve legitimate needs, such as an allergy to an inactive ingredient or a dose unavailable commercially, but the reason should be specific.

Estriol deserves its own line: there is no FDA-approved estriol drug product in the United States. A US estriol cream is compounded by definition.

If you use a compounded vaginal preparation, ask for six exact facts:

1. Which hormone or hormones it contains
2. The concentration per gram or per dose
3. The number of grams or milliliters per application
4. The schedule and intended duration
5. Whether the prescriber intends local or systemic effects
6. Why an FDA-approved product was not a fit

With those answers, a clinician can classify the regimen. Without them, “vaginal” is not enough information.

---

Do you need routine ultrasounds, biopsies, or hormone blood tests?

Not routinely if you are asymptomatic and using recommended low-dose local vaginal estrogen. The 2025 AUA/SUFU/AUGS guideline says not to perform endometrial surveillance solely because of low-dose use. Testing becomes appropriate when there is bleeding, an abnormal exam, a relevant history, a nonstandard regimen, or another specific clinical reason.

Blood hormone tests: Estring and other estrogen labels state that serum FSH and estradiol levels have not been shown useful for managing vulvar and vaginal atrophy symptoms. A single estradiol number does not tell you whether your exact uterine lining is safe, nor does it replace product and dose classification.

Ultrasound and biopsy: neither is routine surveillance for every asymptomatic low-dose user. Unnecessary screening can uncover incidental findings that lead to more procedures without improving outcomes.

Evaluation enters the picture when there is something specific to evaluate, including:

• Bleeding or spotting after menopause
• A history of endometrial hyperplasia or endometrial cancer
• An abnormal pelvic examination
• An incidental endometrial finding on imaging
• A prolonged high-dose or unclear regimen
• A sudden change in symptoms that concerns your clinician

The rule is not “never test.” It is do not test everybody merely because the product is low-dose vaginal estrogen.

---

What if you bleed or spot while using vaginal estrogen?

Report postmenopausal bleeding promptly and have it evaluated, regardless of the product or dose. Undiagnosed abnormal genital bleeding is a contraindication or central warning across the labels reviewed here. Do not add progesterone, increase it, or assume the estrogen is “healing the tissue” without letting a clinician identify the source.

What counts:

• Any vaginal bleeding after menopause, including a single spot
• Recurrent bleeding after sex
• Light spotting that keeps returning
• Blood you cannot confidently identify as vaginal rather than urinary or rectal

What not to do:

• Do not add or increase progesterone to make it stop. That does not diagnose the cause.
• Do not stop every prescription and wait in silence. Contact the prescriber first unless urgent symptoms require immediate care.
• Do not rely on an old normal ultrasound. New bleeding is a new question.

Evaluation may involve a history, pelvic examination, transvaginal ultrasound, endometrial sampling, or another test depending on your age, anatomy, risk factors, and what the clinician finds. The exact workup is individualized.

Most postmenopausal bleeding is not endometrial cancer. That is comforting. It is not permission to ignore it.

---

Does a breast, endometrial, or other cancer history change the answer?

A cancer history changes whether and how vaginal estrogen is used more than it changes whether you should add progesterone yourself. Low-dose vaginal estrogen may still be considered in selected survivors after nonhormonal options, but that decision belongs with the clinicians who know the cancer type, treatment, recurrence risk, and current medications.

Breast cancer history: moisturizers and lubricants are generally tried first. The Endocrine Society recommends shared decision-making that includes the treating oncologist when symptoms persist and low-dose vaginal estrogen is being considered. The conversation is especially careful for women taking an aromatase inhibitor because those drugs depend on very low estrogen exposure.

Endometrial cancer history: this belongs with gynecologic oncology or the treating gynecologist. The general low-dose rule is not a substitute for tumor-specific history and treatment details.

Prior endometrial hyperplasia: individualized. A clinician may recommend monitoring, a different product, or a progestogen for reasons the general population guidance does not capture.

What this page will not tell you is that vaginal estrogen is universally safe after every estrogen-sensitive cancer. That would go beyond the evidence.

---

What changed with FDA estrogen warnings in 2026?

On February 12, 2026, the FDA listed six menopause hormone products with updated prescribing information. Estring was the only topical vaginal estrogen in that first group. Its boxed warning was removed. The other low-dose vaginal estrogen labels reviewed for this page still carried older class-warning language as of August 7, 2026.

The six products on the FDA's current update page are:

• Prometrium
• Divigel
• Cenestin
• Enjuvia
• Estring
• Bijuva

Two details matter here.

One: Estring's update does not mean every vaginal product changed at once. FDA labeling changes occur product by product. Imvexxy, 10 mcg estradiol inserts, estradiol cream, Premarin Vaginal Cream, and Femring still showed older boxed-warning language in the labels reviewed for this page.

Two: Intrarosa's lack of a boxed warning is not part of the estrogen-label rollout. Intrarosa is prasterone, not an estrogen product. Osphena still has its own boxed warning because it has endometrial agonist and cardiovascular-risk language.

So if your friend's Estring paperwork looks calmer than the insert in your Imvexxy or cream box, neither of you is imagining it. You are reading labels on different regulatory schedules.

This is the fastest-moving section on the page. We re-check the FDA tracker monthly.

---

What should you ask your prescriber?

Bring the exact product, strength, and weekly schedule. A specific question about a specific regimen gets a specific answer; “Do I need progesterone with vaginal estrogen?” often gets a generic answer copied from the broadest warning. Your goal is not to win an argument. It is to make the exception, if one exists, visible.

Use this sentence:

“I'm using [product] at [strength], [amount] [how often]. My understanding is that routine progestogen is not recommended for a low-dose local regimen. Do you agree, or is there something in my history, another estrogen, or this dose that changes it?”

The five questions worth writing down:

1. Is my exact product and schedule considered low-dose local therapy?
2. Do I use any systemic estrogen — including Femring, a patch, pill, gel, spray, pellet, or injection?
3. Do I have a uterus or residual endometrial tissue that needs protection?
4. If I take progesterone now, what was it prescribed for: endometrial protection, sleep, bleeding control, or something else?
5. What symptoms should make me call, and when should this regimen be reassessed?

Bring the actual boxes or photos of every pharmacy label, your grams-per-week if you use cream, your operative report if surgery is unclear, and a complete medication list from every clinician.

Want the question list matched to your situation? Use Find My HRT Path before the appointment and take the result with you.

---

What if your prescriber will not discuss the dose or the guideline difference?

Most women reading this do not need a new provider. If you are on a standard low-dose product, have no bleeding, and now understand why the insert sounds different from the guideline, the correct next step may cost nothing: keep taking the prescription as directed and raise the question at your next visit.

That is the honest answer, even though it does not earn a click.

A menopause-focused second opinion becomes reasonable when a clinician will not identify your product, will not discuss the grams or schedule, tells you every vaginal product is systemic, or refuses to evaluate bleeding appropriately.

Using The HRT Index Verification Standard, we separate FDA-approved and compounded finished products, verify published pricing and insurance statements, and assess providers in this exact order: clinical legitimacy, care quality, medication fit, price transparency, access.

Midi Health is one possible route for women who want an insurance-oriented menopause visit. As verified August 7, 2026, Midi says it is available in all 50 states, is in-network with most PPO plans, charges $250 for an initial self-pay visit and $150 for continued-care visits, and notes that coverage, deductibles, coinsurance, and copays vary by plan.

The damaging admission belongs right beside that recommendation: Midi is not covered by Medicare or Medicare-related plans. Medicare beneficiaries may use self-pay but cannot submit Midi-related claims. Midi also says it cannot treat Medicaid or Medi-Cal patients, even as self-pay patients. If either public program is your coverage, start with your own gynecologist, primary care clinician, or another locally covered service instead.

Another correction that matters: Midi offers FDA-approved options and separate compounded Custom Rx products. It is not accurate to describe Midi as FDA-approved-only. If your goal is the evidence base mapped on this page, say plainly that you want an FDA-approved low-dose local product unless there is a specific reason it does not fit.

We are not routing this page toward compounded-first vaginal programs. Their exact finished formulas cannot be placed cleanly on the FDA-label dose and endometrial-evidence ladder above.

If your current clinician has hit a wall and the insurance facts fit, use Find My HRT Path to compare an online menopause visit with the in-person route your situation may require. The HRT Index may earn a commission if a matched provider link leads to care, at no added cost to you. See our affiliate disclosure.

---

How did The HRT Index verify this page?

We reviewed current product labels, converted labeled schedules into weekly amounts, and cross-checked the result against major guidelines and peer-reviewed endometrial evidence. We did not use testimonials as safety evidence, did not assign a numeric provider score, and did not treat a compounded finished product as equivalent to an FDA-approved drug.

The label set reviewed August 7, 2026:

• Imvexxy 4 and 10 mcg
• Estradiol vaginal inserts 10 mcg
• Estring
• Femring
• Estradiol vaginal cream 0.01%
• Premarin Vaginal Cream
• Intrarosa
• Osphena

The weekly dose figures are our arithmetic on the labeled values. They compare the amount placed or released, not the amount absorbed.

The main evidence set includes The Menopause Society's 2020 and 2022 statements, the Endocrine Society guideline, SOGC Guideline 422b, the 2025 AUA/SUFU/AUGS guideline, the WHI observational analysis, and the 2019 systematic review.

We deliberately did not use a patient quote here. “I used it for six years and was fine” is not evidence that another woman's uterus is protected. On this question, documents beat anecdotes.

Recency plan: FDA label rollout monthly; product labels and provider facts quarterly; guideline set at least annually and whenever a major society publishes an update. The date at the top changes only after re-verification.

---

Frequently asked questions

These answers close the follow-up questions most likely to change the decision: cream dose, Estring versus Femring, hysterectomy or ablation, bleeding, other systemic estrogen, cancer history, monitoring, and compounded products. They do not replace the product-specific sections above when your regimen falls outside standard low-dose local use.

Do you have to take progesterone with vaginal estrogen?

Usually not if you use a recommended low-dose local product on its own. Femring, high-dose vaginal cream, and any separate systemic estrogen change the answer. Do not stop progesterone you already take until you know why it was prescribed.

Do you need progesterone with vaginal estrogen cream?

Often not at a standard maintenance dose, but cream is not one dose. Check the concentration, grams per application, and applications per week. High-dose vaginal creams can produce systemic estrogen levels and may require endometrial protection if you have a uterus.

Do you need progesterone with Estring?

Not routinely for Estring alone. It releases 7.5 mcg estradiol daily and is a low-dose local treatment. Its boxed warning was removed in February 2026. Another systemic estrogen in your regimen can still create a progesterone requirement.

Do you need progesterone with Femring?

Generally yes if you have a uterus. Femring delivers 0.05 or 0.10 mg estradiol daily, treats hot flashes, and is systemic estrogen. Its patient information says adding a progestin is generally recommended for a woman with a uterus.

Can you use vaginal estrogen without progesterone if you have a uterus?

Yes, that is the standard guideline approach for recommended low-dose local vaginal estrogen. Having a uterus creates the possibility of needing protection, but product and dose decide whether the estrogen exposure is the kind that requires it.

Does vaginal estrogen cause endometrial cancer?

Available evidence has not shown an increased endometrial cancer risk with recommended low-dose local use. Randomized long-term data beyond one year are limited, so any postmenopausal bleeding still needs prompt evaluation.

Why does my package insert warn about uterine cancer?

Several low-dose products still carry broad estrogen class warnings and tell women with a uterus to discuss a progestogen. Specialty guidelines separately conclude that a routine progestogen is not needed with recommended low-dose local therapy. The label and guideline are answering the risk question at different levels of specificity.

What if I use an estrogen patch and vaginal estrogen together?

The patch determines the endometrial-protection requirement. If you have a uterus and take progesterone with systemic estrogen, do not stop it because the vaginal product does not independently require it.

Do you need progesterone with vaginal estrogen after a hysterectomy?

Not for uterine protection after a confirmed total hysterectomy. Residual endometriosis can create a separate reason to discuss a progestogen. Ablation and an unclear “partial hysterectomy” are not the same as a confirmed total hysterectomy.

What if I had an endometrial ablation?

Ablation does not remove the uterus and may leave residual endometrium. A standard low-dose local product may still follow the usual low-dose rule, but systemic estrogen requires an individualized endometrial-protection plan.

Should I take progesterone if vaginal estrogen causes spotting?

Do not add or increase progesterone on your own. Report postmenopausal spotting and have the cause evaluated. Treating the signal before diagnosing it can delay the right workup.

Do I need routine ultrasounds or biopsies while using vaginal estrogen?

Not solely because you use recommended low-dose local vaginal estrogen and have no symptoms. Testing is appropriate for bleeding, a relevant history, an abnormal examination or scan, or another specific clinical concern.

Do estradiol blood tests tell me whether the regimen is safe?

No single blood value settles the endometrial question. Product, dose, route, uterus status, bleeding, and other estrogen matter more, and product labels state that serum FSH and estradiol levels have not been shown useful for managing vulvar and vaginal atrophy symptoms.

Is compounded vaginal estrogen treated the same as FDA-approved vaginal estrogen?

No. Compounded finished products are not FDA-approved and do not automatically have FDA-reviewed formulation-specific pharmacokinetic or endometrial-safety data. Ask for the exact ingredients, concentration, dose, schedule, intended effect, and reason for compounding.

Can you use vaginal estrogen after breast cancer?

Sometimes, after nonhormonal options, through shared decision-making with the treating oncology and gynecology team. The decision is especially careful with aromatase inhibitors. This page does not declare it universally safe.

---

Still not sure which HRT program is right for you? Take our free matching quiz.

Find My HRT Path — answer a few questions about your symptoms, state, insurance, uterus status, and medication preferences to get a personalized starting-point plan. It also flags when online care is not the right first step. About 90 seconds, free, and no email required.

---

Sources

Medical and regulatory claims on this page are grounded in current prescribing information, major society guidance, and peer-reviewed studies. Provider pricing and insurance statements are traced to the provider's own current pages and dated. Product labels and the FDA warning rollout should be rechecked before each substantive update.

Guidelines and peer-reviewed evidence

1. The Menopause Society. The 2020 genitourinary syndrome of menopause position statement. Menopause. 2020;27(9):976–992.
2. The Menopause Society. The 2022 hormone therapy position statement. Menopause. 2022;29(7):767–794.
3. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(11):3975–4011.
4. Johnston S, Bouchard C, Fortier M, et al. Guideline No. 422b: Menopause and Genitourinary Health. J Obstet Gynaecol Can. 2021.
5. American Urological Association, SUFU, AUGS. Genitourinary Syndrome of Menopause Guideline. 2025.
6. Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause. 2018;25(1):11–20.
7. Constantine GD, Graham S, Lapane K, et al. Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review. Menopause. 2019;26(7):800–807.
8. Mirkin S, Simon JA, Liu JH, et al. Evaluation of endometrial progesterone receptor expression after exposure to a low-dose vaginal estradiol insert. Menopause. 2021;28(9):998–1003.

FDA and current prescribing information

1. US FDA. Menopausal Hormone Therapies with Updated Prescribing Information. Checked August 7, 2026.
2. Imvexxy prescribing information. DailyMed.
3. Estradiol vaginal inserts 10 mcg prescribing information. DailyMed.
4. Estring prescribing information, revised February 2026. US FDA.
5. Femring prescribing information. DailyMed.
6. Estradiol Vaginal Cream USP 0.01% prescribing information. DailyMed.
7. Premarin Vaginal Cream prescribing information. Pfizer labeling, current US prescribing information.
8. Intrarosa prescribing information. DailyMed.
9. Osphena prescribing information. DailyMed.

Additional product and surgical references

1. Vagifem 10 mcg prescribing information. DailyMed.
2. Yuvafem 10 mcg prescribing information. DailyMed.
3. Intrarosa 6.5 mg Summary of Product Characteristics. UK electronic Medicines Compendium.
4. Prometrium prescribing information, revised February 2026. US FDA.
5. Sasaki KJ, Cholkeri-Singh A, Sulo S, Miller CE. Persistent bleeding after laparoscopic supracervical hysterectomy. JSLS. 2014;18(4).
6. American College of Obstetricians and Gynecologists. Endometrial Ablation. Accessed August 7, 2026.

Provider facts

1. Midi Health. Pricing and insurance. Checked August 7, 2026.
2. Midi Health. How Midi works. Checked August 7, 2026.
3. Midi Health. Sexual wellness and nationwide availability. Checked August 7, 2026.
4. Midi Health. FDA-approved hormone therapy options. Checked August 7, 2026.
5. Midi Health. Midi Custom Rx. Checked August 7, 2026.

---

Educational research — not medical advice, and not medically reviewed by a clinician. Do not start, stop, or change estrogen or progesterone based on this page alone. Your product, dose, uterus status, other hormone therapy, bleeding history, cancer history, and personal risk factors can change the answer. Contact a licensed clinician promptly for bleeding or spotting after menopause.

The HRT Index is published by The HRT Index LLC. See our editorial standards, medical review policy, corrections policy, and affiliate disclosure.